Acorda Therapeutics, Inc.
ACOR · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $20,289 | $37,985 | $27,715 | $29,675 |
| % Growth | -46.6% | 37.1% | -6.6% | – |
| Cost of Goods Sold | $3,707 | $13,289 | $3,387 | $3,065 |
| Gross Profit | $16,582 | $24,696 | $24,328 | $26,610 |
| % Margin | 81.7% | 65% | 87.8% | 89.7% |
| R&D Expenses | $954 | $1,009 | $1,207 | $1,550 |
| G&A Expenses | $0 | $21,825 | $0 | $21,825 |
| SG&A Expenses | $28,371 | $22,206 | $23,152 | $21,825 |
| Sales & Mktg Exp. | $0 | $381 | $0 | $0 |
| Other Operating Expenses | $11 | -$158 | $403 | $1 |
| Operating Expenses | $29,969 | $23,215 | $32,050 | $31,066 |
| Operating Income | -$19,628 | $1,481 | -$2,519 | -$3,632 |
| % Margin | -96.7% | 3.9% | -9.1% | -12.2% |
| Other Income/Exp. Net | -$5,244 | -$257,351 | -$4,888 | -$4,004 |
| Pre-Tax Income | -$27,281 | -$255,870 | -$9,943 | -$11,346 |
| Tax Expense | $114 | -$38,109 | -$1,055 | -$1,965 |
| Net Income | -$27,395 | -$217,761 | -$8,888 | -$9,381 |
| % Margin | -135% | -573.3% | -32.1% | -31.6% |
| EPS | -22.06 | -225.81 | -7.16 | -7.55 |
| % Growth | 90.2% | -3,053.8% | 5.2% | – |
| EPS Diluted | -22.06 | -225.81 | -7.16 | -7.55 |
| Weighted Avg Shares Out | 1,242 | 964 | 1,242 | 1,242 |
| Weighted Avg Shares Out Dil | 1,242 | 964 | 1,242 | 1,242 |
| Supplemental Information | – | – | – | – |
| Interest Income | $207 | $222 | $157 | $58 |
| Interest Expense | $8,057 | $9,200 | $7,827 | $7,715 |
| Depreciation & Amortization | $882 | $7,923 | $7,691 | $7,691 |
| EBITDA | -$12,666 | -$230,764 | $372 | $3,236 |
| % Margin | -62.4% | -607.5% | 1.3% | 10.9% |